AR088043A1 - Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato - Google Patents

Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Info

Publication number
AR088043A1
AR088043A1 ARP120103551A ARP120103551A AR088043A1 AR 088043 A1 AR088043 A1 AR 088043A1 AR P120103551 A ARP120103551 A AR P120103551A AR P120103551 A ARP120103551 A AR P120103551A AR 088043 A1 AR088043 A1 AR 088043A1
Authority
AR
Argentina
Prior art keywords
methyl
aminosulfonyl
phenyl
thiazol
acetamide
Prior art date
Application number
ARP120103551A
Other languages
English (en)
Spanish (es)
Inventor
Dr Schwab Wilfried
Dr Birkmann Alexander
Vgtli Kurt
Dr Rehse Joachim
Dr Lender Andreas
Dr Grunenberg Alfons
D Keil Birgit
I-Dr Haag Dieter
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of AR088043A1 publication Critical patent/AR088043A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ARP120103551A 2011-09-26 2012-09-26 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato AR088043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11007823A EP2573086A1 (en) 2011-09-26 2011-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Publications (1)

Publication Number Publication Date
AR088043A1 true AR088043A1 (es) 2014-05-07

Family

ID=46889067

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP120103551A AR088043A1 (es) 2011-09-26 2012-09-26 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
ARP190102595A AR116394A2 (es) 2011-09-26 2019-09-13 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
ARP200102938A AR120291A2 (es) 2011-09-26 2020-10-23 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-triazol-2-il]n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP190102595A AR116394A2 (es) 2011-09-26 2019-09-13 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
ARP200102938A AR120291A2 (es) 2011-09-26 2020-10-23 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-triazol-2-il]n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Country Status (29)

Country Link
US (1) US9340535B2 (enExample)
EP (3) EP2573086A1 (enExample)
JP (2) JP6161614B2 (enExample)
KR (4) KR20170055565A (enExample)
CN (2) CN105541829A (enExample)
AR (3) AR088043A1 (enExample)
AU (2) AU2012314536B2 (enExample)
BR (1) BR112014003245B1 (enExample)
CA (1) CA2791142C (enExample)
CL (1) CL2014000149A1 (enExample)
DK (2) DK2598501T3 (enExample)
ES (2) ES2462492T3 (enExample)
HK (1) HK1220978A1 (enExample)
HR (1) HRP20140351T1 (enExample)
IL (2) IL230152A (enExample)
IN (1) IN2014DN01993A (enExample)
JO (2) JO3037B1 (enExample)
MX (2) MX338736B (enExample)
MY (2) MY190878A (enExample)
PE (1) PE20141148A1 (enExample)
PH (2) PH12014500567A1 (enExample)
PL (2) PL2598501T3 (enExample)
PT (1) PT2598501E (enExample)
RU (2) RU2669388C1 (enExample)
SG (1) SG10201407430TA (enExample)
TW (2) TWI567070B (enExample)
UA (2) UA115317C2 (enExample)
WO (1) WO2013045479A1 (enExample)
ZA (2) ZA201401773B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
TWI706940B (zh) * 2016-04-06 2020-10-11 德商創新分子有限責任公司 新穎之抗病毒化合物
US11266636B2 (en) 2016-11-28 2022-03-08 Aicuris Gmbh & Co. Kg Maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
UY37497A (es) * 2016-11-28 2018-06-29 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
CA3045059A1 (en) * 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
IL271725B2 (en) 2017-06-28 2025-09-01 Aicuris Anti Infective Cures Ag Intravaginally applicable devices comprising antiviral compounds
UA126163C2 (uk) 2017-10-05 2022-08-25 Інновейтів Молекьюлз Ґмбх Енантіомери серії противірусних сполук
US11964969B2 (en) 2018-07-06 2024-04-23 Phaeno Therapeutics Co., Ltd Crystal forms of thiazole compound and application thereof
JP7640452B2 (ja) * 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度peg脂質及びそれらの使用
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
KR20220160024A (ko) * 2020-03-26 2022-12-05 아이쿠리스 게엠베하 운트 코. 카게 N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제
JP2025527943A (ja) 2022-08-29 2025-08-25 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規な結晶形態
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
JP2025530762A (ja) 2022-08-29 2025-09-17 アセンブリー・バイオサイエンシーズ・インコーポレイテッド ヘルペスウイルス用医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129717A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP2007314516A (ja) * 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
CN101490001A (zh) * 2006-06-09 2009-07-22 Icos股份有限公司 用作dp-2拮抗剂的取代的苯乙酸
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range

Also Published As

Publication number Publication date
EP2598501A1 (en) 2013-06-05
PH12014500567A1 (en) 2014-04-14
KR20170055565A (ko) 2017-05-19
WO2013045479A1 (en) 2013-04-04
JP6353022B2 (ja) 2018-07-04
TWI532739B (zh) 2016-05-11
PL2602258T3 (pl) 2014-08-29
JP2014528948A (ja) 2014-10-30
ZA201408734B (en) 2016-08-31
MX338736B (es) 2016-04-29
NZ718867A (en) 2016-05-27
PH12015502801A1 (en) 2016-10-03
RU2620604C2 (ru) 2017-05-29
ZA201401773B (en) 2015-12-23
IL230152A (en) 2015-04-30
MX2014003389A (es) 2014-07-09
AR120291A2 (es) 2022-02-09
AU2012314536A1 (en) 2014-02-06
ES2462492T3 (es) 2014-05-23
SG10201407430TA (en) 2014-12-30
PH12015502801B1 (en) 2016-10-03
MX371088B (es) 2020-01-16
JO3734B1 (ar) 2021-01-31
DK2598501T3 (da) 2014-04-22
HK1220978A1 (zh) 2017-05-19
TWI567070B (zh) 2017-01-21
TW201317234A (zh) 2013-05-01
MY190878A (en) 2022-05-13
CA2791142A1 (en) 2013-03-26
RU2669388C1 (ru) 2018-10-11
PL2598501T3 (pl) 2014-08-29
CA2791142C (en) 2017-08-01
RU2014107430A (ru) 2015-11-10
CL2014000149A1 (es) 2014-09-05
PT2598501E (pt) 2014-06-25
UA119574C2 (uk) 2019-07-10
KR20180088530A (ko) 2018-08-03
CN105541829A (zh) 2016-05-04
EP2598501B1 (en) 2014-03-12
BR112014003245A2 (pt) 2017-03-01
ES2466221T3 (es) 2014-06-09
MY185063A (en) 2021-04-30
EP2602258B1 (en) 2014-03-19
JP6161614B2 (ja) 2017-07-12
JO3037B1 (ar) 2016-09-05
KR20140066704A (ko) 2014-06-02
CN103842359A (zh) 2014-06-04
EP2573086A1 (en) 2013-03-27
PE20141148A1 (es) 2014-09-15
CN103842359B (zh) 2016-05-25
BR112014003245B1 (pt) 2021-11-09
AU2015260762B2 (en) 2016-06-09
NZ621615A (en) 2016-04-29
AR116394A2 (es) 2021-05-05
ES2466221T8 (es) 2016-09-13
EP2602258B8 (en) 2016-09-28
KR20190104249A (ko) 2019-09-06
EP2602258A1 (en) 2013-06-12
TW201625603A (zh) 2016-07-16
US9340535B2 (en) 2016-05-17
IN2014DN01993A (enExample) 2015-05-15
AU2012314536B2 (en) 2016-01-14
DK2602258T3 (da) 2014-04-22
UA115317C2 (uk) 2017-10-25
IL234405A (en) 2015-04-30
KR101768295B1 (ko) 2017-08-14
AU2015260762A1 (en) 2016-02-04
HRP20140351T1 (hr) 2014-07-04
JP2017114859A (ja) 2017-06-29
US20140221433A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
AR088043A1 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
IL256624A (en) Pharmaceuticals and their pharmaceutical preparations for the treatment of inflammatory disorders
AR083213A1 (es) Proceso de preparacion de derivados pirimidinicos, compuestos intermediarios y proceso para prepararlos
JP2014528948A5 (enExample)
AR091651A1 (es) Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
RU2010145171A (ru) Аналоги галихондрина в
AR089134A1 (es) Arilos y heteroarilos biciclicos inhibidores de los canales de sodio
JP2016510323A5 (enExample)
JP2012515142A5 (enExample)
WO2014132270A3 (en) Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
EA201591205A1 (ru) Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры
AR105091A1 (es) Procedimiento para la síntesis de derivados de rapamicina
CY1124179T1 (el) Βελτιωμενη μεθοδος παρασκευης ριβαροξαμπανης με χρηση νεων ενδιαμεσων ενωσεων
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
MX373700B (es) Composicion acuosa novedosa.
EA201490998A1 (ru) Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)-уксусной кислоты
JP2016516790A5 (enExample)
RU2016134404A (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
UY33511A (es) Procedimiento de obtención de la forma cristalina ii del febuxostat
SI2935255T1 (en) PROCEDURE FOR PREPARATION OF RIVAROKSABAN
RU2017142996A (ru) Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма
WO2014136047A3 (en) A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
WO2015022702A3 (en) Process for preparation of 4,5-dimethoxybenzene derivatives and use in the synthesis of ivabradine and salts thereof
JP2015524456A5 (enExample)
JP2014144922A5 (enExample)

Legal Events

Date Code Title Description
FC Refusal